Stereotaxis received U.S. FDA clearance for its Magic magnetic interventional ablation catheter, marking the device maker’s first proprietary robotic ablation catheter authorized for use in the United States. Company statements said the approval supports Stereotaxis’ shift from a robotics supplier toward an integrated electrophysiology technology portfolio and enables the firm to commercialize a catheter designed to work with its magnetic navigation systems. The regulatory milestone follows prior commercial and regulatory steps that Stereotaxis highlighted as catalysts for growth. The clearance will let the company pursue U.S. commercialization and potentially bundle the catheter with navigation solutions for electrophysiology labs; competitive adoption will depend on clinical uptake and reimbursement pathways.